The development of small molecule inhibitors of BCL2 family anti-apoptotic proteins resulted in a paradigm shift for the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) (Roberts, 2020). This evidence concerns the gene BCL2 and hematologic disorder.